Adc Therapeutics SA [ADCT] stock is trading at $5.01, down -2.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ADCT shares have gain 3.94% over the last week, with a monthly amount glided 87.64%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference. In a post published today on Yahoo Finance, ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 at 9:50 a.m. ET.
From an analyst’s perspective:
Adc Therapeutics SA [NYSE: ADCT] stock has seen the most recent analyst activity on August 10, 2023, when JP Morgan upgraded its rating to a Neutral. Previously, BofA Securities downgraded its rating to Underperform on April 24, 2023, and dropped its price target to $2. On December 06, 2022, CapitalOne initiated with a Overweight rating and assigned a price target of $12 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $7 on November 09, 2022. JP Morgan initiated its recommendation with a Overweight and recommended $5 as its price target on September 21, 2022. Morgan Stanley downgraded its rating to Equal-Weight for this stock on September 09, 2022, and downed its price target to $11. In a note dated November 09, 2021, Wolfe Research initiated an Outperform rating and provided a target price of $44 on this stock.
Adc Therapeutics SA [ADCT] stock has fluctuated between $0.36 and $6.04 over the past year. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Adc Therapeutics SA [NYSE: ADCT] shares were valued at $5.01 at the most recent close of the market. An investor can expect a potential return of 169.46% based on the average ADCT price forecast.
Analyzing the ADCT fundamentals
Adc Therapeutics SA [NYSE:ADCT] reported sales of 122.57M for the trailing twelve months, which represents a drop of -81.01%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.83 points at the first support level, and at 4.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.26, and for the 2nd resistance point, it is at 5.50.
Adc Therapeutics SA [ADCT] reported earnings per share of -$0.58 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.63/share, meaning a difference of $0.05 and a surprise factor of 7.90%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.58 per share as compared to estimates of -$0.46 per share, a difference of -$0.12 representing a surprise of -26.10%.
Ratios To Look Out For
For context, Adc Therapeutics SA’s Current Ratio is 4.80. In addition, the Quick Ratio stands at 4.51 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 3.30.
